Company Announcement / Press release Archives - Page 14 of 18

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

Press release, Solna on 26 March 2020 The following resolution was passed at the extraordinary general meeting in Xspray Pharma AB (publ) today, on 26 March 2020. Adoption of incentive programme The extraordinary general meeting resolved, in accordance with the board’s proposal, to adopt a long-term incentive programme for a number of employees of Xspray. According […]

The conditions for Xspray Pharma’s listing on Nasdaq Stockholm have been fulfilled

STOCKHOLM – March 26, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020, that the company had received clearance for a listing on Nasdaq Stockholm, following the fulfilment of customary conditions. Xspray Pharma has today received information that the conditions have been fulfilled and accordingly, Xspray Pharma’s first day of trading on […]

Xspray Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

STOCKHOLM – March 23, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020 that Nasdaq Stockholm’s listing committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market. Today, on 23 March, the prospectus that has been prepared by the company in connection with the listing was […]

Xspray Pharma approved for listing on Nasdaq Stockholm

STOCKHOLM – March 18, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that Nasdaq Stockholm’s listing committee has approved the company’s application to be listed on Nasdaq Stockholm’s main market. The approval is conditional upon the fulfilment of customary conditions, among others that a prospectus is approved and registered by the Swedish Financial Supervisory […]

Xspray receives notification of manufacturing approval and provides update on clinical studies

STOCKHOLM – March 17, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces today that its production partner, Nerpharma, has received approval from Italian Medicines Agency (AIFA) for the full-scale production facility in Milan, Italy. The approval applies to clinical trial use ofamorphous material based on the company’s HyNap technology. The company also announces […]

Xspray Pharma publishes Interim report Q4, January – December 2019

PRESS RELEASE February 28, 2020 “One important milestone was reached in June when our production facility in Italy was completed and was able to do a test run. We have now proven that our technology is possible to scale up – and we are the first in the world to manufacture amorphous material in the […]

Notice of extraordinary general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to an extraordinary general meeting on Thursday 26 March 2020 at 16.00 CET at Advokatfirman Vinge’s office on Stureplan 8 in Stockholm. Registration starts at 15.30 CET. Right to attend the general meeting Shareholders who wish to attend the general meeting must: be […]

Three additional product patents in the US for HyNap-Dasa

STOCKHOLM – February 18, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that the United States Patent and Trademark Office (USPTO) has granted Xspray three new US patent for HyNap-Dasa. The new patents, US10,561,643; US 10,561,644; and US10,561,645, are valid until January 2033. This means that Xspray now has seven product patents for […]

Additional product patent in the US for HyNap-Dasa

STOCKHOLM – February 12, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that the United States Patent and Trademark Office (USPTO) has granted Xspray a new US patent for HyNap-Dasa. The new patent, US 10,555,937, covers the pharmaceutical composition of the company's primary product candidate, HyNap-Dasa. This is Xspray's fourth product patent in […]

Stability studies initiated with Xspray’s HyNap-Dasa tablets

STOCKHOLM – February 11, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that the stability studies with the company’s commercially manufactured HyNap-Dasa tablets began today, February 11. The readout of the study results after six months will be a part of the company’s ANDA application (Abbreviated New Drug Application) for market approval in the US for […]